glp-1 receptor agonists weight loss effectiveness for reduction in people living with obesity but without diabetes: a living benefit–harm modelling study Rx Trends: Real-World Data on
Description
The composite primary endpoint occurred in 6.5% of patients in the semaglutide group versus 8.0% of patients in the placebo group (hazard ratio [HR] = 0.80
This is the easy part
Weight loss data
Tirzepatide and the related class of dual GLP-1R and GIPR agonists thus offer the promise to achieve superior long-term glycemic control with a significant reduction of obesity (38, 39)
Oral GLP-1s are oral medications that work by mimicking glucagon-like peptide-1 (GLP-1), a gut hormone involved in appetite and blood sugar regulation
